Search research articles
Contact Us
Filters
Showing results (51-60 of 58) with videos related to
Page
of 6
Sort By:
You have reached the last page of results.
This site can display upto 58 results.
Bone Marrow Transplantation
|
June 27, 2012
Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL
P Kebriaei, T Madden, X Wang, et al.
Leukemia
|
February 28, 2015
Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma
N Shah, P F Thall, P S Fox, et al.
Leukemia
|
September 23, 2016
PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies
M H Qazilbash, E Wieder, P F Thall, et al.
Blood
|
February 7, 2001
Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation
S Giralt, P F Thall, I Khouri, et al.
Leukemia
|
November 9, 2007
Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome
M de Lima, R E Champlin, P F Thall, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 27, 2013
A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer
J A Ajani, L Xiao, J A Roth, et al.
Cancer
|
December 18, 2001
Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck
J E Tseng, B S Glisson, F R Khuri, et al.
Bone Marrow Transplantation
|
December 20, 2016
Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients
B S Andersson, P F Thall, B C Valdez, et al.
Page
of 6
Search research articles
Search
Showing results (51-60 of 58) with videos related to
Sort By:
Page
of 6
You have reached the last page of results.
This site can display upto 58 results.
Bone Marrow Transplantation
|
June 27, 2012
Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL
P Kebriaei, T Madden, X Wang, et al.
Leukemia
|
February 28, 2015
Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma
N Shah, P F Thall, P S Fox, et al.
Leukemia
|
September 23, 2016
PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies
M H Qazilbash, E Wieder, P F Thall, et al.
Blood
|
February 7, 2001
Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation
S Giralt, P F Thall, I Khouri, et al.
Leukemia
|
November 9, 2007
Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome
M de Lima, R E Champlin, P F Thall, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 27, 2013
A phase II randomized trial of induction chemotherapy versus no induction chemotherapy followed by preoperative chemoradiation in patients with esophageal cancer
J A Ajani, L Xiao, J A Roth, et al.
Cancer
|
December 18, 2001
Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck
J E Tseng, B S Glisson, F R Khuri, et al.
Bone Marrow Transplantation
|
December 20, 2016
Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients
B S Andersson, P F Thall, B C Valdez, et al.
Page
of 6